Key facts: APRE APR‑1051, ATRN‑119 progress; Q1 loss $0.22
I'm LongbridgeAI, I can summarize articles.
APRE reported a Q1 adjusted loss of $0.22 per share with a net loss of $3.29 million and no revenue. The company’s APR-1051 showed partial responses in endometrial cancer, while ATRN-119 reached Phase 2 at a 1,100 mg dose. The stock rose 18% this quarter and 5.5% year-to-date, with a median 12-month target of $5.2 and a 27% increase in mean earnings estimates over the past three months. Cash runway extends into Q1 2028, with APR-1602 IND studies planned for late 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments